Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
about
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisIxabepilone for the treatment of solid tumors: a review of clinical dataChemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience.Vasodilatation in the rat dorsal hindpaw induced by activation of sensory neurons is reduced by paclitaxelGenetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trialChronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation.Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathy.Emerging drugs to replace current leaders in first-line therapy for breast cancer.Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionPeripheral neuropathy induced by paclitaxel: recent insights and future perspectives.Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinomaCYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelRegulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.Paclitaxel: a review of adverse toxicities and novel delivery strategies.CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathyGlobal variation in CYP2C8-CYP2C9 functional haplotypesPharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Pharmacogenomics of paclitaxel.Level of evidence for therapeutic drug monitoring of taxanes.Germline pharmacogenetics of paclitaxel for cancer treatment.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Metabolism of the taxanes including nab-paclitaxel.Mass spectrometry in the pharmacokinetic studies of anticancer natural products.Personalizing chemotherapy dosing using pharmacological methods.Treatment regimens of classical and newer taxanes.Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study.Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy.Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome.C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes.Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
P2860
Q28077780-A4F0B0EF-23BA-40B2-8C50-3D8EE77931E5Q28271570-29A56E68-C8FF-4252-B5C8-9AF1663B9B38Q33984071-51C72434-51C8-494B-9A3A-1479E98ACF80Q34538185-B19D13C3-99CC-466D-9996-F7D80278F944Q34633385-11954F4A-BBCB-449A-BE1E-CF874E3E3787Q35037971-023CDE5A-9E29-4AD0-8F84-F78C5805440EQ35865061-E236EABA-C7E5-4210-B104-DE92E515ADEBQ36073448-0362B582-229A-4492-BE9D-3C68A5194452Q36580598-8306C389-88BC-4635-B4F4-B67763E290E4Q36611760-B38C3163-59C7-423E-9356-62880B39038CQ36635810-62B14B97-FC3A-4F67-ADE8-C7C491506A65Q36726598-4EB13BCE-EA5A-4C12-B024-A203C55F632DQ36802118-70F61892-6566-48A8-B26C-B4A88A599BA9Q36862832-D11AF61C-9EAB-4563-8365-A0D561DC3E8CQ36877796-C7EC74D8-F6F2-4D09-9EB4-00397001F8DDQ36940993-DFC116E4-3C05-4B1B-97B9-8D809D0B6F11Q36945032-2A128E88-FBC4-47D5-AAFE-E0F763B6CB20Q37055326-32722EC6-1E60-46A4-B535-1923DC803D0AQ37187663-00C520C1-AEBA-4B88-AC37-651E4366A345Q37321909-D3C0E1F2-FF54-4FC1-A585-F36941FD61A5Q37417070-38887829-A9EB-4A60-80BF-1B7D90A18E04Q37434738-B028027B-C1B3-4241-95ED-FA6C837C91C7Q37684533-2E34AB89-D319-4D09-A451-0E33F786BFD7Q37736449-3304DC54-E586-43A3-98B0-78E47AF60B2BQ37788732-948C3F99-DC33-49DD-9B72-1F7426AFD130Q38120289-314F56B6-A80C-49A9-9DD3-15B2C63B94A2Q38130410-5D06ED2F-52C2-4BA7-A800-78C72FFF0B87Q38267987-92BCBEE1-F26A-4911-8A78-AC5CDA0C2615Q38568180-2DBC5C0C-ACF0-4B32-93B1-C981B6AA2C55Q38571728-6AA7134E-BF32-40FB-B0F2-716437FCB8C1Q38641136-CF41CBA9-4951-470B-968F-3B41D0BD78DFQ38722948-F0589C49-39F1-4548-83F5-A415C7C0A2ECQ38726616-16244719-00CB-4229-8D7F-33C0BE7EDBF9Q38948699-8BD8AA0E-2EEC-4361-A9AB-BDA3F0F2486EQ39796533-A83D36E7-260B-4787-BA60-C6831B994698Q41227394-D23FC508-C901-4236-9092-399CF5F2A3D2Q41244234-6FA67256-7418-4129-8E69-056BCF419A78Q42379504-1711F9FF-B3B7-4CBA-AF4A-85107688EE2EQ43268653-D7A575F1-7221-4E08-B9B9-64A129B6674AQ43496569-13BA872E-C05F-45F5-8DFE-F92827B8043C
P2860
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Association of Paclitaxel phar ...... patients with advanced cancer.
@en
Association of Paclitaxel phar ...... patients with advanced cancer.
@nl
type
label
Association of Paclitaxel phar ...... patients with advanced cancer.
@en
Association of Paclitaxel phar ...... patients with advanced cancer.
@nl
prefLabel
Association of Paclitaxel phar ...... patients with advanced cancer.
@en
Association of Paclitaxel phar ...... patients with advanced cancer.
@nl
P2093
P1476
Association of Paclitaxel phar ...... patients with advanced cancer.
@en
P2093
Clemens Unger
Dirk Behringer
Hans Gelderblom
Klaus Mross
Seth M Steinberg
P304
P356
10.1158/1078-0432.CCR-05-0298
P407
P577
2005-07-01T00:00:00Z